assessing parp inhibition and brca1/2 as a prognostic biomarker in mcrpc
Published 1 year ago • 72 plays • Length 2:48Download video MP4
Download video MP3
Similar videos
-
3:56
parp inhibitors: activity in brca1 versus brca2 altered mcrpc
-
7:04
testing for brca germline mutations in the clinic and the mechanism of action of parp inhibitors
-
6:05
mechanisms of resistance to parp inhibitor or platinum chemotherapy in brca1/2 mutated metastati...
-
12:07
parp inhibitors in brca1/2-mutated patients in prostate cancer
-
1:52
parpi for somatic brca1/2 and other dna repair gene mutations in women with metastatic breast cancer
-
11:49
brca & parp inhibitors: targeted chemotherapy | #markscholzmd #alexscholz @pcri
-
16:22
role of parp inhibitors in prostate cancer
-
6:21
parp inhibition in brca1/2 or hrd- ovarian cancer
-
1:38
updates in parp inhibition for ovarian cancer
-
5:41
biomarker analysis of olaparib with or without cediranib in mcrpc
-
6:40
overcoming resistance to parpi in brca1-deficient breast cancer with sting agonists
-
2:47
what is a parp inhibitor? | dana-farber cancer institute | science illustrated
-
0:27
parp inhibitors #short
-
1:22
overcoming resistance to parp inhibition in ovarian cancer
-
44:25
targeted cancer therapy: choosing the right assay to assess parp inhibitors
-
5:40
parp inhibitors in advanced prostate cancers
-
1:01
choosing the correct parp inhibitor for prostate cancer
-
1:02:31
parp inhibitors: assessing the clinical trial landscape
-
2:01:14
act genomics dinner symposium | moving from brca1/2 to hrd: beyond woman’s cancers